Meta-analysis of efficacy of Chinese medicine compound combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cai, Yunxiang [1 ]
Zhong, Huaping [2 ]
Huang, Zhenhe [1 ,3 ]
机构
[1] Ganzhou Peoples Hosp, Dept Otolaryngol Head & Neck Surg, Ganzhou, Jiangxi, Peoples R China
[2] Gannan Med Coll, Affiliated Hosp 1, Dept Cardiovasc Med, Ganzhou, Jiangxi, Peoples R China
[3] Ganzhou Peoples Hosp, Dept Otolaryngol Head & Neck Surg, 16 Meiguan Ave, Ganzhou 341000, Jiangxi, Peoples R China
来源
关键词
Locally advanced nasopharyngeal carcinoma; radiotherapy; chemotherapy; Chinese medicine compound; meta-analysis; SHENQI FUZHENG INJECTION; SOPHORA-FLAVESCENS; GASTRIC-CANCER;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Nasopharyngeal carcinoma is a prevalent malignant tumor in clinical practice, with the highest incidence rate among otorhinolaryngological malignant tumors. Objectives: This study aims to comprehensively evaluate the clinical efficacy and safety of traditional Chinese medicine compound (CMC) combined with concur-rent radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (LA-NPC). Methods: Relevant essays published before November 20, 2021, were retrieved from China National Knowledge Internet (CNKI), China Science and Technology Journal Database (CQVIP), Wanfang database, PubMed, and Web of Science databases. Randomized controlled trials regarding the clinical efficacy of CMC combined with concur-rent radiotherapy and chemotherapy in the treatment of LA-NPC were included. Results: A total of 15 publications involving 1324 patients were included in this study, including 665 in the experimental group and 659 in the control group. Meta-analyses revealed that compared with radiotherapy or chemotherapy only, CMC combined with con-current radiotherapy and chemotherapy for LA-NPC significantly improved the efficacy [risk ratio (RR)=1.15, 95% confidence interval (95% CI) (1.09, 1.20), P<0.00001], the quality of life [RR=1.35, 95% CI (1.13, 1.62), P=0.0009], immune function indices CD4+ levels [RR=6.2, 95% CI (3.64, 8.76), P<0.00001], CD4+/CD8+ [RR=0.33, 95% CI (0.14, 0.53), P=0.0009], and alleviated the decrease in white blood cell counts [RR=0.67, 95% CI (0.52, 0.86), P=0.002]. Conclusion: CMC combined with concurrent radiotherapy and chemotherapy for the treatment of LA-NPC can significantly improve the efficacy and reduce severe adverse reactions caused by conventional radiotherapy and chemotherapy. However, due to limitations in the quantity and quality of the included studies, more high-quality, multi-center, and large sample-size studies are needed to provide high-level and high-quality medical evidence for systematic evaluation.
引用
收藏
页码:4439 / 4453
页数:15
相关论文
共 50 条
  • [21] Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma
    Baujat, B.
    Audry, H.
    Bourhis, J.
    Chan, A. T. C.
    Onat, H.
    Chua, D. T. T.
    Kwong, D. L. W.
    Al-Sarraf, M.
    Chi, K. H.
    Hareyama, M.
    Leung, S. F.
    Thephamongkhol, K.
    Pignon, J. P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04):
  • [22] Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma
    Cheng, SH
    Liu, TW
    Jian, JJM
    Tsai, SYC
    Hao, SP
    Huang, CH
    Liu, MC
    Yu, B
    Huang, AT
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1997, 3 (02): : 100 - 106
  • [23] Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis
    Xiao, Lifeng
    Kang, Wenyi
    Liao, Jiayu
    Li, Yuru
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2022, 88 : S70 - S81
  • [24] Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: A meta-analysis
    Guan, Hui
    He, Yan
    Su, Yonglin
    Wei, Zhigong
    Liu, Zheran
    Wang, Jingjing
    He, Ling
    Mu, Xiaoli
    Li, Ruidan
    Hu, Xiaolin
    Peng, Xingchen
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (08): : 2332 - 2341
  • [25] Effect of cetuximab combined with IMRT and concurrent chemotherapy in treating locally advanced nasopharyngeal carcinoma
    Yang, Pei
    Liu, Jing
    Yong, Hui
    Ma, Jianli
    Gao, Xiaoping
    JOURNAL OF BUON, 2021, 26 (01): : 138 - 144
  • [26] TREATMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA WITH INDUCTION CHEMOTHERAPY (CYSPLATIN plus EPIRUBICIN) FOLLOWED BY RADIOTHERAPY AND CONCURRENT CYSPLATIN
    Gabriele, Anna Maria
    Airoldi, Mario
    Garzaro, Massimiliano
    Raimondo, Luca
    Condello, Cecilia
    Beatrice, Fabio
    Pecorari, Giancarlo
    Giordano, Carlo
    ANNALS OF ONCOLOGY, 2009, 20
  • [27] Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone on locally advanced nasopharyngeal carcinoma
    Liu, H.
    Ding, X. R.
    Song, Y. Q.
    Jiang, C.
    Zhong, X. M.
    Hui, H. X.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2020, 34 (06): : 2115 - 2119
  • [28] Efficacy and Safety of Chemotherapy Combined with Stereotactic Radiotherapy in the Treatment of Nasopharyngeal Carcinoma
    Shan, Guo-Ping
    Wang, Bing-Bing
    Zhang, Peng
    Du, Feng-Lei
    Yang, Yi-Wei
    MEDICAL SCIENCE MONITOR, 2017, 23 : 5630 - 5636
  • [29] Accelerated hyperfractionated radiotherapy with concurrent chemotherapy in locally advanced nasopharyngeal carcinoma:: a phase II study
    Fischer, M
    Stüben, G
    Klahold, M
    Stuschke, M
    Budach, V
    Sack, H
    Jahnke, K
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (08) : 507 - 511
  • [30] Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma - A time-to-event meta-analysis
    Song, Yaqi
    Wang, Wanwei
    Tao, Guangzhou
    Zhou, Xilie
    ORAL ONCOLOGY, 2015, 51 (08) : 764 - 769